Clinical trials: Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers
- Trial name
- NCT07103278
- Testing
- AD-116, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Prostatic Hyperplasia
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin…
- Trial name
- NCT02058368
- Testing
- Dutasteride 0.5mg capsules, Tamsulosin 0.2mg tablets
- Where
- 46 sites in China, Japan and 2 more
- Volunteers
- 607 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia, Prostatitis
Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)
Multicentric, national, prospective, parallel group, controlled. The Subjects in every center will be randomized and assigned to the pharmacologic arm or the one with the biochemical monitoring
- Trial name
- NCT00169585
- Testing
- Levofloxacin oral tablets
- Where
- 19 sites in Italy
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms
Reliability of Home Uroflowmetery Using a Disposable Digital Device
The FloRite™ device is a disposable urine flow meter, indicated for use in a home setting. The device provides Urofowmetry measurements, similar to clinic's measurements.
- Trial name
- NCT02026674
- Testing
- FloRite
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Flometrica Ltd.
Benign Prostatic Hyperplasia
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
- Trial name
- NCT07444385
- Testing
- AD-116, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Prostatic Hyperplasia
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia
- Trial name
- NCT02245555
- Testing
- Tamsulosin
- Volunteers
- 1,060 people
- Sponsor
- Boehringer Ingelheim
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation
Benign Prostatic Hyperplasia (BPH)
Post-Market Study to Assess iTind Safety in Comparison to UroLift
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
- Trial name
- MT-08 (NCT04757116)
- Testing
- iTind, UroLift
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 256 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia
Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate
The purpose of this ex-vivo study is to evaluate the insertion procedure for the ProstaPlant implant in human prostates and the support that it supplies to the prostate.
- Trial name
- NCT00468026
- Testing
- ProstaPlant Stent
- Where
- Israel
- Sponsor
- ProstaPlant Urology System Ltd.
Benign Prostatic Hyperplasia (BPH)
To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.
The main goal of this study is to evaluate the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System for treatment of enlarged prostate (BPH) symptoms.
- Trial name
- REBOUND (NCT07592299)
- Testing
- Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- ALPFA Medical
Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS)
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
This is a prospective, randomized, open-label, parallel-group post-market clinical trial (PMCT). The overall objective of this PMCT is to compare the effectiveness, durability, and patient-centered outcomes of the Zenflow Spring…
- Conditions
- Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS), Enlarged Prostate
- Trial name
- NCT07797348
- Testing
- Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin
- Volunteers
- 110 people
- Sponsor
- Zenflow, Inc.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
- Trial name
- NCT00386009
- Testing
- Tadalafil
- Where
- 13 sites in United States, Greece and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with…
- Trial name
- NCT00409357
- Testing
- SL77.0499-10 (alfuzosin hydrochloride)
- Where
- Japan
- Volunteers
- 473 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hypertrophy (BPH)
A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects
This study is a randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate the effects of food on the bioavailability of CKD-397 after a single oral dose in healthy male subjects
- Trial name
- NCT02615782
- Testing
- CKD-397
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Embosphere® PROstate Post Market Study
Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.
- Trial name
- PROstate (NCT03527589)
- Testing
- Prostate artery embolization
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 499 people
- Sponsor
- Merit Medical Systems, Inc.
Benign Prostatic Hyperplasia
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH.
- Trial name
- NCT00347061
- Testing
- afuzosin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Sanofi
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.